What is LOPJLB’s current signal on KRYS?

LOPJLB’s latest quantitative signal on Krystal Biotech, Inc. (KRYS) is SELL in a BEAR regime. Signals are updated daily.

What market regime is KRYS in?

Krystal Biotech, Inc. (KRYS) is currently classified in the BEAR HMM market regime on LOPJLB.

What does Krystal Biotech, Inc. (KRYS) do?

Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several …

Krystal Biotech, Inc. (KRYS)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$321.16-3.29%Close

SELLBEAR · day 17

Company news

defenseworld.net · 2d ago

2,490 Shares in Krystal Biotech, Inc. $KRYS Purchased by Terra Nova Asset Management LLC

seekingalpha.com · 5d ago

Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value

fool.com · 6d ago

Breakfast News: Week in Review

fool.com · 8d ago

Breakfast News: 10 Moves to Fatten Your Nest Egg

defenseworld.net · 28d ago

Corient Private Wealth LP Grows Stock Position in Krystal Biotech, Inc. $KRYS

defenseworld.net · 34d ago

Hsbc Holdings PLC Invests $3.65 Million in Krystal Biotech, Inc. $KRYS

zacks.com · 41d ago

Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?

globenewswire.com · 42d ago

Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference

zacks.com · 42d ago

Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?

247wallst.com · 62d ago

Here Are Friday’s Top Wall Street Analyst Research Calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, Sandisk, T-Mobile US, Wayfair, and More

zacks.com · 71d ago

Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus

seekingalpha.com · 72d ago

Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript

marketbeat.com · 73d ago

Krystal Biotech Q2 Earnings Call Highlights

zacks.com · 73d ago

Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates

globenewswire.com · 73d ago

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

seekingalpha.com · 78d ago

Krystal Biotech: International Expansion And A Vibrant Pipeline

seekingalpha.com · 78d ago

Krystal Biotech: Profitable, Self-Funding, And Loaded With Optionality

zacks.com · 80d ago

Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?

defenseworld.net · 81d ago

Assetmark Inc. Makes New Investment in Krystal Biotech, Inc. $KRYS

fool.com · 82d ago

These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead

Market news & ticker search · RSS for KRYS

FAQ

What is LOPJLB’s current signal on KRYS?: LOPJLB’s latest quantitative signal on Krystal Biotech, Inc. (KRYS) is SELL in a BEAR regime. Signals are updated daily.
What market regime is KRYS in?: Krystal Biotech, Inc. (KRYS) is currently classified in the BEAR HMM market regime on LOPJLB.
What does Krystal Biotech, Inc. (KRYS) do?: Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several …

Krystal Biotech, Inc. (KRYS)

Key stats

Industry peers

Prediction markets

Company news

FAQ